The present invention relates to the use of organic and highly water-soluble compatible solutes or a solute mixture, preferably in the form of an inhalable, oropharyngeally, nasally and intravenously administrable composition, in the prevention or treatment of diseases caused by ss(+)RNA viruses of the Coronavriridae family, preferably of those diseases caused by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63 and/or HCoV-229E. Particularly suitable solutes in the meaning of the invention are ectoine and its derivatives, Glycoin, mannosylglycerate (Firoin) and mannosylglyceramide (Firoin-A), which, due to their strong water-binding capacity, reduce the binding of the viruses to the receptors of the host cell in the transitional epithelium, e.g. eye, in the internal epithelium, e.g. lung, and in the endothelium and thus reduce or prevent the multiplication of the viruses. According to the invention, prevention is enabled by a reduced infectious sputum and breath, and treatment and rehabilitation of the affected tissues is enabled by the membrane protective properties of the compatible solutes according to the invention.

Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

An improved agent and treatment method for a broad variety of diseases in both animals and humans is disclosed. The agent is an inventive composition comprising a bacterial-based culture. Particularly, the inventive composition disclosed herein is an active molecule produced by a Gram-negative bacterial strain that is a member of the genus Brevundimonas. Consumption of the inventive composition by way of liquid or dry feed produces a broad range of health benefits and has proven effective in the prevention and treatment of disease. The bacterium of the disclosed composition selectively modulates Toll-like receptors (TLRs) for the prevention and treatment of disease such as coccidiosis. Specific actions include but are not limited to improvement of gut health, acceleration or enhancement of immune response using a natural immune modulator, and the promotion of animal growth.

An improved agent and treatment method for a broad variety of diseases in both animals and humans is disclosed. The agent is an inventive composition comprising a bacterial-based culture. Particularly, the inventive composition disclosed herein is an active molecule produced by a Gram-negative bacterial strain that is a member of the genus Brevundimonas. Consumption of the inventive composition by way of liquid or dry feed produces a broad range of health benefits and has proven effective in the prevention and treatment of disease. The bacterium of the disclosed composition selectively modulates Toll-like receptors (TLRs) for the prevention and treatment of disease such as coccidiosis. Specific actions include but are not limited to improvement of gut health, acceleration or enhancement of immune response using a natural immune modulator, and the promotion of animal growth.

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

A Panax plant extract and a pharmaceutical composition and the use thereof. The mass ratio of Rk1 and Rg5 in the Panax plant extract is 1:1.0-1.5, and the content of Rg3, Rg5 and Rk1 in the extract is relatively high. The extract can be used to prepare a drug for treating chronic heart failure, coronary stable angina, arrhythmia, diabetes and complications thereof, Meniere's disease, hyperlipemia, fatty liver, Alzheimer's disease, dymenorrhea, metabolic syndrome, gout, tumours or vascular leak syndrome.

A Panax plant extract and a pharmaceutical composition and the use thereof. The mass ratio of Rk1 and Rg5 in the Panax plant extract is 1:1.0-1.5, and the content of Rg3, Rg5 and Rk1 in the extract is relatively high. The extract can be used to prepare a drug for treating chronic heart failure, coronary stable angina, arrhythmia, diabetes and complications thereof, Meniere's disease, hyperlipemia, fatty liver, Alzheimer's disease, dymenorrhea, metabolic syndrome, gout, tumours or vascular leak syndrome.

Described herein are composition of ascarosides, methods of using them, and the like for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for modifying a microbiome of a patient (e.g., for treatment of gut microbiome dysfunction).

Described herein are composition of ascarosides, methods of using them, and the like for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for modifying a microbiome of a patient (e.g., for treatment of gut microbiome dysfunction).